Correction to: Comparative Effectiveness, Time to Discontinuation, and Patient-Reported Outcomes with Baricitinib in Rheumatoid Arthritis: 2-Year Data from the Multinational, Prospective Observational RA-BE-REAL Study in European Patients
- Open Access
- 20.11.2025
- Correction
Erschienen in:
Correction: Rheumatol Ther (2023) 10:1575–1595 https://doi.org/10.1007/s40744-023-00597-3
In Table 4 of this article, entry for ‘B–non-TNFi’ in the column ‘LDA’ was incorrect as ‘40 (30.4)’ and should have been ‘48 (30.4)’. The footnote cue ‘*’ symbol and its corresponding text were missing in this table and should have read as shown in the corrected table.
Anzeige
Incorrect version of Table 4:
Table 4
Mean CFB in clinical outcomes and proportion of patients achieving CDAI remission or low disease activity for overall, b/tsDMARD-naïve, b/tsDMARD-experienced, < 65-year-old, and ≥ 65-year-old patients at 24 months
Number | CDAI | Pain VAS CFB | HAQ-DI CFB | |||
|---|---|---|---|---|---|---|
CFB | REM, n (%) | LDA, n (%) | ||||
Overall | ||||||
A–baricitinib 4 mg | 302 | − 15.0 (12.4) | 58 (24.4) | 100 (42.0) | − 23.9 (31.0) | − 0.4 (0.7) |
A–baricitinib 2 mg | 34 | − 17.1 (12.4) | 6 (21.4) | 17 (60.7) | − 28.4 (27.0) | − 0.5 (0.7) |
B–TNFi | 337 | − 7.2 (11.3) | 53 (16.2) | 119 (36.4) | − 13.4 (24.3) | − 0.2 (0.5) |
B–non-TNFia | 161 | − 6.1 (11.0) | 12 (7.6) | 40 (30.4) | − 10.5 (25.3) | − 0.2 (0.4) |
B–tsDMARD | 65 | − 7.7 (10.6) | 13 (21.0) | 22 (35.5) | − 16.3 (27.5) | − 0.2 (0.5) |
b/tsDMARD-naïve | ||||||
A–baricitinib 4 mg | 137 | − 14.8 (12.7) | 28 (26.2) | 48 (44.9) | − 24.2 (30.4) | − 0.4 (0.7) |
A–baricitinib 2 mg | 18 | − 17.7 (11.0) | 4 (25.0) | 10 (62.5) | − 26.8 (26.0) | − 0.5 (0.8) |
B–TNFi | 253 | − 7.8 (11.6) | 44 (17.9) | 96 (39.0) | − 15.1 (25.7) | − 0.2 (0.5) |
B–non-TNFia | 67 | − 7.6 (11.8) | 8 (12.3) | 30 (46.2) | − 9.5 (28.3) | − 0.2 (0.5) |
B–tsDMARD | 24 | − 6.7 (8.1) | 6 (26.1) | 9 (39.1) | − 17.3 (22.6) | − 0.2 (0.5) |
b/tsDMARD-experienced | ||||||
A–baricitinib 4 mg | 165 | − 15.2 (12.2) | 30 (22.9) | 52 (39.7) | − 23.7 (31.7) | − 0.3 (0.7) |
A–baricitinib 2 mg | 16 | − 16.4 (14.5) | 2 (16.7) | 7 (58.3) | − 30.9 (29.6) | − 0.4 (0.5) |
B–TNFi | 84 | − 5.5 (10.3) | 9 (11.1) | 23 (28.4) | − 8.2 (18.6) | − 0.2 (0.4) |
B–non-TNFia | 94 | − 5.0 (10.2) | 4 (4.3) | 18 (19.4) | − 11.3 (22.9) | − 0.1 (0.4) |
B–tsDMARD | 41 | − 8.3 (11.8) | 7 (17.9) | 13 (33.3) | − 15.8 (30.2) | − 0.3 (0.4) |
< 65 | ||||||
A–baricitinib 4 mg | 222 | − 13.8 (12.1) | 41 (23.7) | 71 (41.0) | − 21.2 (30.9) | − 0.3 (0.7) |
A–baricitinib 2 mg | 6 | − 18.2 (11.8) | 0 (0) | 4 (80.0) | − 40.4 (6.6) | − 0.5 (0.7) |
B–TNFi | 253 | − 12.1 (12.8) | 41 (24.6) | 62 (37.1) | − 19.6 (30.7) | − 0.3 (0.7) |
B–non-TNFia | 100 | − 9.4 (9.5) | 7 (13.5) | 24 (46.2) | − 10.4 (25.3) | − 0.2 (0.5) |
B–tsDMARD | 40 | − 10.9 (15.3) | 5 (27.8) | 4 (22.2) | − 16.8 (32.9) | − 0.2 (0.8) |
≥ 65 | ||||||
A–baricitinib 4 mg | 80 | − 18.4 (12.7) | 17 (26.2) | 29 (44.6) | − 30.9 (30.6) | − 0.4 (0.8) |
A–baricitinib 2 mg | 28 | − 16.9 (12.7) | 6 (26.1) | 13 (56.5) | − 26.1 (28.9) | − 0.5 (0.7) |
B–TNFi | 84 | − 11.5 (11.2) | 10 (24.4) | 19 (46.3) | − 18.6 (26.0) | − 0.2 (0.5) |
B–non-TNFia | 61 | − 14.3 (14.7) | 6 (20.7) | 12 (41.4) | − 11.1 (33.3) | − 0.1 (0.6) |
B–tsDMARD | 25 | − 8.7 (15.5) | 3 (27.3) | 1 (9.1) | − 12.6 (45.0) | − 0.2 (0.7) |
Correct version of Table 4:
Table 4
Mean CFB in clinical outcomes and proportion of patients achieving CDAI remission or low disease activity for overall, b/tsDMARD-naïve, b/tsDMARD-experienced, < 65-year-old, and ≥ 65-year-old patients at 24 months
Number | CDAI | Pain VAS CFB | HAQ-DI CFB | |||
|---|---|---|---|---|---|---|
CFB | REM, n (%) | LDA, n (%) | ||||
Overall | ||||||
A–baricitinib 4 mg | 302 | − 15.0 (12.4) | 58 (24.4) | 100 (42.0) | − 23.9 (31.0) | − 0.4 (0.7) |
A–baricitinib 2 mg | 34 | − 17.1 (12.4) | 6 (21.4) | 17 (60.7) | − 28.4 (27.0) | − 0.5 (0.7) |
B–TNFi | 337 | − 7.2 (11.3) | 53 (16.2) | 119 (36.4) | − 13.4 (24.3) | − 0.2 (0.5) |
B–non-TNFi*a | 161 | − 6.1 (11.0) | 12 (7.6) | 48 (30.4) | − 10.5 (25.3) | − 0.2 (0.4) |
B–tsDMARD* | 65 | − 7.7 (10.6) | 13 (21.0) | 22 (35.5) | − 16.3 (27.5) | − 0.2 (0.5) |
b/tsDMARD-naïve | ||||||
A–baricitinib 4 mg | 137 | − 14.8 (12.7) | 28 (26.2) | 48 (44.9) | − 24.2 (30.4) | − 0.4 (0.7) |
A–baricitinib 2 mg | 18 | − 17.7 (11.0) | 4 (25.0) | 10 (62.5) | − 26.8 (26.0) | − 0.5 (0.8) |
B–TNFi* | 253 | − 7.8 (11.6) | 44 (17.9) | 96 (39.0) | − 15.1 (25.7) | − 0.2 (0.5) |
B–non-TNFi*a | 67 | − 7.6 (11.8) | 8 (12.3) | 30 (46.2) | − 9.5 (28.3) | − 0.2 (0.5) |
B–tsDMARD* | 24 | − 6.7 (8.1) | 6 (26.1) | 9 (39.1) | − 17.3 (22.6) | − 0.2 (0.5) |
b/tsDMARD-experienced | ||||||
A–baricitinib 4 mg | 165 | − 15.2 (12.2) | 30 (22.9) | 52 (39.7) | − 23.7 (31.7) | − 0.3 (0.7) |
A–baricitinib 2 mg | 16 | − 16.4 (14.5) | 2 (16.7) | 7 (58.3) | − 30.9 (29.6) | − 0.4 (0.5) |
B–TNFi* | 84 | − 5.5 (10.3) | 9 (11.1) | 23 (28.4) | − 8.2 (18.6) | − 0.2 (0.4) |
B–non-TNFi*a | 94 | − 5.0 (10.2) | 4 (4.3) | 18 (19.4) | − 11.3 (22.9) | − 0.1 (0.4) |
B–tsDMARD* | 41 | − 8.3 (11.8) | 7 (17.9) | 13 (33.3) | − 15.8 (30.2) | − 0.3 (0.4) |
< 65 | ||||||
A–baricitinib 4 mg | 222 | − 13.8 (12.1) | 41 (23.7) | 71 (41.0) | − 21.2 (30.9) | − 0.3 (0.7) |
A–baricitinib 2 mg | 6 | − 18.2 (11.8) | 0 (0) | 4 (80.0) | − 40.4 (6.6) | − 0.5 (0.7) |
B–TNFi | 253 | − 12.1 (12.8) | 41 (24.6) | 62 (37.1) | − 19.6 (30.7) | − 0.3 (0.7) |
B–non-TNFia | 100 | − 9.4 (9.5) | 7 (13.5) | 24 (46.2) | − 10.4 (25.3) | − 0.2 (0.5) |
B–tsDMARD | 40 | − 10.9 (15.3) | 5 (27.8) | 4 (22.2) | − 16.8 (32.9) | − 0.2 (0.8) |
≥ 65 | ||||||
A–baricitinib 4 mg | 80 | − 18.4 (12.7) | 17 (26.2) | 29 (44.6) | − 30.9 (30.6) | − 0.4 (0.8) |
A–baricitinib 2 mg | 28 | − 16.9 (12.7) | 6 (26.1) | 13 (56.5) | − 26.1 (28.9) | − 0.5 (0.7) |
B–TNFi | 84 | − 11.5 (11.2) | 10 (24.4) | 19 (46.3) | − 18.6 (26.0) | − 0.2 (0.5) |
B–non-TNFia | 61 | − 14.3 (14.7) | 6 (20.7) | 12 (41.4) | − 11.1 (33.3) | − 0.1 (0.6) |
B–tsDMARD | 25 | − 8.7 (15.5) | 3 (27.3) | 1 (9.1) | − 12.6 (45.0) | − 0.2 (0.7) |
The first two paragraphs under the section “LDA and Remission” were incorrect and have now been corrected.
Anzeige
LDA and Remission (Incorrect Text)
For unadjusted results at 24 months, 41.1% of patients overall treated with baricitinib and 36.4% (TNFi), 30.4% (non-TNFi), and 35.5% (tsDMARD) of patients in cohort B achieved LDA (Table 4). Remission was achieved by 15.2% of patients treated with baricitinib and by 16.2% (TNFi), 7.6% (non-TNFi), and 21.0% (tsDMARD) in cohort B.
Among those naïve to b/tsDMARD therapy, LDA was achieved by 46.6% of patients treated with baricitinib, and 39.0% (TNFi), 46.2% (non-TNFi), and 39.1% (tsDMARD) of patients in cohort B. Among naïve patients treated with baricitinib, 18.1% achieved remission, while 17.9% receiving TNFi, 12.3% receiving non-TNFi, and 26.1% receiving tsDMARDs in cohort B achieved remission. For those with previous b/tsDMARD experience, LDA was achieved by 36.2% of patients treated with baricitinib, and 28.4% (TNFi), 19.4% (non-TNFi), and 33.3% (tsDMARD) of patients in cohort B. Remission was achieved by 12.7% of patients treated with baricitinib, while 11.1% (TNFi), 4.3% (non-TNFi), and 17.9% (tsDMARD) of patients in cohort B achieved remission. Compared to patients experienced to b/tsDMARD therapy, naïve patients achieved an overall higher rate of LDA and remission (Table 4).
LDA and Remission (Correct Text)
For unadjusted results using the NRI approach, at 24 months, 41.1% of patients overall treated with baricitinib and 36.4% (TNFi), 30.4% (non-TNFi), and 35.5% (tsDMARD) of patients in cohort B achieved LDA (Table 4). Using the NRI approach, remission was achieved by 15.2% of patients treated with baricitinib and by 16.2% (TNFi), 7.6% (non-TNFi), and 21.0% (tsDMARD) in cohort B.
Among those naïve to b/tsDMARD therapy, the NRI approach showed that LDA was achieved by 46.6% of patients treated with baricitinib, and 39.0% (TNFi), 46.2% (non-TNFi), and 39.1% (tsDMARD) of patients in cohort B. Among naïve patients treated with baricitinib, 18.1% achieved remission, while 17.9% receiving TNFi, 12.3% receiving non-TNFi, and 26.1% receiving tsDMARDs in cohort B achieved remission. For those with previous b/tsDMARD experience, using NRI LDA was achieved by 36.2% of patients treated with baricitinib, and 28.4% (TNFi), 19.4% (non-TNFi), and 33.3% (tsDMARD) of patients in cohort B. Remission was achieved by 12.7% of patients treated with baricitinib, while 11.1% (TNFi), 4.3% (non-TNFi), and 17.9% (tsDMARD) of patients in cohort B achieved remission, when the NRI approach was employed. Compared to patients experienced to b/tsDMARD therapy, naïve patients achieved an overall higher rate of LDA and remission (Table 4).
The original article has been corrected.
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
